SEARCH

SEARCH BY CITATION

References

  • 1
    Ginès P, Ages P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 18191827.
  • 2
    Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729737.
  • 3
    Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis. Perspectives in the age of MELD. HEPATOLOGY 2003; 37: 393400.
  • 4
    Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 271: 11211125.
  • 5
    Kew MC, Brunt PW, Varma RR, Hourigan KJ, Williams HS, Sherlock S. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971; 2: 504510.
  • 6
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodé J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988; 8: 11511157.
  • 7
    Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38(Suppl): S6989.
  • 8
    Arroyo V. Milestones on liver disease. A commentary on Hecher R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. J Hepatol 2002; 36: 315320.
  • 9
    Guevara M, Ginè P, Fernández-Esparrach G, Sort P, Salmeron JM, Jiménez Wet et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. HEPATOLOGY 1998; 27: 3541.
  • 10
    Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 56570.
  • 11
    G̈ulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. HEPATOLOGY 1999; 30: 870875.
  • 12
    Uriz J, Ginès P, Cardenas A. Sort P, Jiménez W, Salieron JM, et al. Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 4348.
  • 13
    Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J,et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 1519.
  • 14
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A restrospective multicenter study. Gastroenterology 2002; 122: 923930.
  • 15
    Ortega R, Ginès P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study. HEPATOLOGY 2002; 36: 941948.
  • 16
    Angeli P, Volpin R, Gerunda G, Bragihero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. HEPATOLOGY 1999; 29: 16901697.
  • 17
    Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002; 36: 374380.
  • 18
    Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2004; 40: 5564.
  • 19
    Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. HEPATOLOGY 1998; 28: 416422.
  • 20
    Kostreva DR, Castaner A, Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980; 238: R390394.
  • 21
    Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. HEPATOLOGY 1996; 14: 600608.
  • 22
    Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role or cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999; 97: 259267.
  • 23
    Moller S, Henriksen JH. Cirrhotic cardiomyopathy. Heart 2002; 87: 915.
  • 24
    Jiménez W, Arroyo V. Origins of cardiac dysfunction in cirrhosis. Gut 2003; 52: 13921394.
  • 25
    Ruiz-del-Arbol L, Urman J, Fernández J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. HEPATOLOGY 2003; 38: 12101218.
  • 26
    Lee S. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy. HEPATOLOGY 2003; 38: 10891091.
  • 27
    Merli M, Valeriano V, Funaro S, Attili AF. Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97: 142148.
    Direct Link:
  • 28
    Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different “effective” blood volume. HEPATOLOGY 2003; 38: 13701377.
  • 29
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 30
    Fernández J, Navasa M, Garcia-Pagan JC, Abraldes JG, Jiménez W, Bosch J, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol. In press.